Bioproduto à base de água de coco e maltodextrina para protocolos de jejum pré-operatório de curta duração

Abstract

The preoperative fasting was instituted many years ago, at the beginning of the anesthetic practice, to ensure the emptying of the stomach contents, avoid bronchial aspiration, vomiting, regurgitation, administration of various drugs to reduce gastric acidity and volume. Preoperative fasting protocols suggest shorter fasting periods especially for liquids, providing more comfort to the patient, and less risk of hypoglycemia and dehydration, without increasing the incidence of perioperative pulmonary aspiration. The aim of the study was to assess whether the bioproduct based on coconut water and maltodextrin (ACP Surgery) supplied the needs of clinical trials of ERAS project (Enhanced Recovery After Surgery) with good tolerance and acceptance. It was conducted a prospective, randomized, controlled, double-blind study in humans with a group of 49 patients at the Santa Casa de Misericordia de Fortaleza, to prove the efficiency and effectiveness of ACP Surgery to achieve the goals and planned effects on ERAS project. The experimental groups were: G1 [control group; Nutri Dextrin (Nutrimed, Fortaleza, Ceará); n = 20) and G2 [intervention; ACP Surgery (ACP Biotecnologia, Fortaleza, Ceará;. N = 29]. In the interval between 10 and 20 hours prior to the surgery, blood sample was taken from each patient and sent to the Hospital's Laboratory of Clinics Analysis for measurement of serum levels of total leukocytes, glucose, sodium, potassium and chlorine. The data were submitted to t test (α = 95%, p> 0.05 and t rejection area > 1.96) and expressed as mean and standard deviation. The G1 (Nutri Dextrin) and G2 (ACP Surgery) showed the following results regarding blood tests: total leukocyte G1 = 11,322.64 + 5,033.94, and G2 = 11,074.14 + 4,480.35; sodium G1 = 140.8 + 4.14 mEq/L, and G2 = 139.3 + 4.38 mEq/L; potassium G1 = 4.16 + 0.65 mEq/L, and G2 = 4.18 + 0.47 mEq/L; chloro G1 = 107.4 + 4.69 mEq/L, and G2 = 107.1 + 6.88 mEq/L; and glucose G1 = 130.3 + 39.96 mg/dL, and G2 = 123.9 + 36.47 mg/dL. In all variables p> 0.05, so it can be considered that Nutri Dextrin and ACP Surgery products are equivalent. The acceptance of the ACP Surgery was 97%, with no reports of cough or nausea (100% tolerance), without loss of palatability. It follows that the produced bioproduct met the needs and specifications of preoperative fasting protocols of short duration, showing acceptance and tolerance compatible with the commercial product at the same time reducing costs and facilitating protocol implement.